The National Institutes of Health (NIH) announced a public-private partnership to accelerate the development of COVID-19 vaccine and treatment options. The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership aims to develop an international strategy for a coordinated research response to COVID-19.
The ACTIV partnership will consist of the NIH, biopharmaceutical companies, the Office of the Assistant Secretary for Preparedness and Response (ASPR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the European Medicines Agency. Collaboratively, ACTIV will develop a framework to identify the most promising candidates for COVID-19 vaccines and treatments and streamline the clinical trial and regulatory processes.
The NIH has outlined the following four fast-track focus areas for ACTIV:
- Standardize and share preclinical evaluation methods in an open forum that allows for comparison and validation;
- Prioritize and accelerate clinical evaluation of therapeutic candidates with near-term potential;
- Maximize clinical trial capacity and effectiveness; and
- Advance vaccine development.
The NIH notes that researchers are currently sifting through over 100 potential vaccine and therapeutic candidates and ACTIV will aim to provide guidance to quickly connect candidates to clinical trials.